Our working hypothesis is based on the interplay between vascular dysregulation, neuropathological alterations and decline in AD brain function. In the latent phase vascular dysregulation is already apparent when patients are asymptomatic.…
ID
Source
Brief title
Condition
- Other condition
- Neurological disorders NEC
- Vascular disorders NEC
Synonym
Health condition
cerebrovasculaire dysfunctie
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Cerebrovascular recording methods
Neurovascular coupling studied with non-invasive Doppler-technique
Two 2 MHz-probes are mounted on an individually fitted headband. The P2-segment
of the left posterior cerebral artery (PCA) and the right middle cerebral
artery (MCA) are insonated. The recording of the MCA flow velocity allows
determination for possible non-specific effects in the test situation such as
blood pressure changes, which might affect cerebral circulation. Mean blood
flow velocities are recorded using a Transcranial Doppler device (DWL, Singen,
Germany).
As a stimulation parameter a colour movie is used. The visual stimulation
protocol consists of 10 cycles each with a resting phase of 20 s (eyes closed)
and a stimulating phase of 40 s. Changes between phases are signalled
acoustically using a tone.
Beat-to-beat intervals of cerebral blood flow velocity are interpolated
linearly for an averaging procedure. To assure independence from the insonation
angle and to allow comparisons between the different participants, absolute
data are transformed into relative changes of cerebral blood flow velocity in
relation to baseline. The baseline is calculated from the blood flow velocity
averaged for a time span of 10 s before the beginning of the stimulation phase.
The method and algorithm for analysing the data sets in terms of a control
system are described in detail in Rosengarten (2001). The responses of the ten
test sequences are averaged to improve signal-to-noise ration.
Cerebral autoregulation
The electrocardiogram (ECG) is measured by an in-home made portable
ECG-amplifier. Arterial blood pressure (ABP) is measured using a non-invasive
finger blood pressure monitor (Portapres, TNO) commonly used in studies on
dynamic cerebral autoregulation. The cuff of the right size is placed on the
middle finger of the left hand. A DWL Multidop Transcranial Dopplersonography
device is used to measure the cerebral blood flow velocity (CBFV) in both the
right and left middle cerebral artery (MCA). Two 2 MHz-probes are held in
position by a special frame.
Data analysis
ECG, ABP and right and left-CBFV signals are recorded and on-line digitised and
stored on a PC with an acquisition and analysis software package (AFO new
version 2.33, developed by IDEE Maastricht). The sampling frequency is 250 Hz.
An automatic algorithm detected R-waves from the ECG. Between every two R-waves
the diastolic, systolic and mean values of the blood pressure waveform are
determined. Correspondingly the peak-systolic, end-diastolic and mean CBFV
values are determined. Artefacts are removed by linear interpolation. The
beat-to-beat values of ABP and CBFV are resampled at 5 Hz using
spline-interpolation (8). From the ABP the mean value is subtracted and the
CBFVs are normalised with respect to the mean. This results in zero-mean
signals suited for spectral analysis to estimate the transfer function. The
transfer function is calculated by
(1)
where Sxx(f) is the autospectrum of changes in arterial blood pressure and
Sxy(f) is the cross-spectrum between the ABP- and CBFV-signals. The transfer
function magnitude |H(f)| and phase spectrum *(f) are derived from the real
part HR(f) and imaginary part HI(f) of the complex transfer function as
(2) (3)
The squared coherence function γ2(f) is estimated by (4)
where Syy(f) is the autospectrum of changes in cerebral blood flow velocity.
The squared coherence reflects the strength of the linear relationship between
ABP and CBFV for each frequency on a scale from 0 to 1.
PWV pulse wave velocity
Two pressure waves are recorded transcutaneously at the base of the neck for
the right common artery and over the right femoral artery. PWV is determined as
the foot-to-foot velocity. Pulse transit time was determined as the average of
10 consecutive beats. The distance travelled by the pulse wave is measured over
the body surface as the distance between the 2 recording sites. Aortic PWV is
calculated as the ratio of distance to transit time.
PTT pulse transit time
PTT is the interval between ventricular electrical ECG activity (and arrival of
a peripheral pulse waveform. It is the time needed for the pulse wave to travel
from the aortic valve to the periphery, estimated as the delay between the R
wave in the ECG (start Q-wave) and the arrival of the pulse wave at the finger
as determined by finger finapres measurement.
Secondary outcome
results of neuropsychological tests performed before participation in this
investigation.
results of cerebral neuroimaging (CT and/or MRI) performed before participation
in this investigation.
Background summary
Brain function is critically dependent on continuous blood supply.
Cerebrovascular dysregulation (CVD) can lead to brain dysfunction. Vascular
factors are until recently not thought to play a role in Alzheimer*s disease
(AD). However, an emerging view is that CVD may be a feature of AD. In AD, two
control mechanisms, cerebral neurovascular coupling (NVC) and cerebral
autoregulation (CAR) may be affected. NVC is a measure of brain blood flow
changes in response to a stimulus (light, sound) and CAR keeps blood flow
constant independent of blood pressure variations.
Study objective
Our working hypothesis is based on the interplay between vascular
dysregulation, neuropathological alterations and decline in AD brain function.
In the latent phase vascular dysregulation is already apparent when patients
are asymptomatic. Thereafter cognitive function begins to decline and
neuropathological alterations become manifest. Cerebrovascular control (CVC)
deteriorates in parallel with cognitive function. Major aim is to quantify NVC
and CAR in AD and mild cognitive impairment (MCI) using non-invasive
techniques. Also markers for possible systemic vascular abnormalities (pulse
wave velocity, pulse transit time) will be studied. Recordings will be
performed in definite AD, MCI and controls. Major objective is to verify the
value of CVD testing as marker for early AD diagnosis.
Study design
It concerns an observational investigation in 3 groups namely 20 patients with
probable or possible Alzheimer disease, 20 patients with mild cognitive
impairment and a control group of 20. Among all participants investigations of
the cerebrovascular and systemic vessels will be performed. The tests are
visual neurovascular coupling, cerebral autoregulation, pulse wave velocity and
pulse transition time.
In patients with AD measurements will be perfomed if possible before the
patient is set on specififc anti-alzheimer medication. Use of medication is,
for practicle reasons, no contra-indication.
Study burden and risks
Investigation load and risk for the participants are minimal. For the
cerebrovascular tests the participant is lying supine in a bed. During the
study of neurovascular coupling the participant has to actively view a dynamic
visual stimulus during 40 seconds followed with an eyes closed period of 20
seconds. This sequence is repeated about 10 times.
All measurements are non-invasive, do not form a patient load and are painless.
P. Debyelaan
6202 az
Nederland
P. Debyelaan
6202 az
Nederland
Listed location countries
Age
Inclusion criteria
Alzheimer patients
Alzheimer diagnosed according to the DSM-IV criteria for dementia (American Psychiatric Association, 1994), and NINCDS-ADRDA criteria (McKhann et al., 1984)(probable, possible).
Presence of a reliable informant, who has contact with the patient at least once a week.
Informed consent of the patient before participation into the study.;MCI patients
The descriptions proposed by Petersen et al. (1999) are used to classify MCI.
Informed consent of the patient before participation into the study.;Controls
Informed consent before participation into the study.
Control matching parameters will be age, sex and level of education.
Exclusion criteria
Alzheimer patients
If living in a nursing home at the start of the study.
Patients without a reliable informant.
Diagnosis of Vascular Dementia, according to NINDS/AIREN criteria (Roman et al., 1993)
Presence of micro-vascular pathology as defined by the Fazekas scale (Fazekas, 1987)
Use of psychopharmacological medication.
Abuse of alcohol and/or drugs.
Diabetes
Heart disease
Presence of hypertension will be considered as a co-variate in the analysis.;To exclude patients with a possible stenosis (> 50%) of extra- and/or intracranial vessels a non-invasive and non-aggravating standard duplex investigation will be performed in all subjects. Patients without a temporal *doppler* window will be excluded. In general about 1 out of 10 subjects will have no temporal window. According to this about 22 Alzheimer patients will have to be screened to acquire a group of 20 subjects.;MCI patients
If living in a nursing home at the start of the study.
Use of psychopharmacological medication.
Abuse of alcohol and/or drugs.
Diabetes
Heart disease
Presence of hypertension will be considered as a co-variate.;To exclude patients with a possible stenosis (> 50%) of extra- and/or intracranial vessels a non-invasive and non-aggravating standard duplex investigation will be performed in all subjects.
Patients without a temporal *doppler* window will be excluded. In general about 1 out of 10 subjects will have no temporal window. According to this about 22 MCI patients will have to be screened to acquire a group of 20 subjects.
Controls
Use of psychopharmacological medication.
Abuse of alcohol and/or drugs.
Diabetes
Heart disease;To exclude participants with a possible stenosis (> 50%) of extra- and/or intracranial vessels a non-invasive and non-aggravating standard duplex investigation will be performed in all subjects.
Participants without a temporal *doppler* window will be excluded. In general about 1 out of 10 subjects will have no temporal window. According to this about 22 controls will have to be screened to acquire a group of 20 subjects
Control matching parameters will be age, sex and level of education.
Presence of hypertension will be considered as a co-variate.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL15574.068.07 |